海創藥業(688302.SH):口服PROTAC藥物HP568片中國臨牀試驗完成首例受試者入組
格隆匯1月9日丨海創藥業(688302.SH)公佈,公司自主研發的HP568片用於治療雌激素受體(Estrogen Receptor, ER)陽性和人表皮生長因子受體 2(HumanEpidermal Growth
Factor Receptor,
HER2)陰性的晚期乳腺癌(ER+/HER2-晚期乳腺癌)的臨牀試驗(以下簡稱“該研究”)於近日完成首例受試者入組。
HP568
片是公司自主研發的口服雌激素受體 α(ERα)蛋白降解靶向聯合體(Proteolysis Targeting Chimera, PROTAC)藥物,用於治療
ER+/HER2-晚期乳腺癌。該研究是一項評估口服 HP568 片單藥和聯合哌柏西利在
ER+/HER2-晚期乳腺癌患者中的安全性、耐受性、藥代動力學和初步療效的多中心、開放、劑量遞增/劑量拓展、Ⅰ/Ⅱ期臨牀研究,目前已獲得研究中心的倫理批准,並於近日成功完成首例受試者入組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.